Noxopharm White Paper

15 Disclaimer: Veyonda is currently not approved in Australia or any other country Veyonda® – IONIC program IONIC: Immuno-OncologywithNOX66 (Veyonda) in Combination IONIC aims: • To use Veyonda to overcome resistance to checkpoint inhibitor therapy (CIT) in cancer types where CIT is approved. • To use Veyonda to extend the use of CIT to cancer types currently considered largely unresponsive to CIT. IONIC rationale: • To use immunostimulatory functions of Veyonda (activation of innate immune cells and CD-4+ and CD-8+ T cells; increased trafficking of T-cells to restore immune function to tumours) to complement the PD-1/PD-L1 inhibitory effects of CIT. IONIC program objectives: To show that... • Veyonda can increase the tumour response rate to CIT in patients with cancer types considered able to respond to CIT. • Veyonda also can make cancer types considered typically unresponsive to CIT (< 5% response rate) become more responsive to CIT. IONIC-1 Phase 1b trial combining Veyonda® with the immune checkpoint inhibitor, Opdivo® (nivolumab), for the treatment of a range of tumour types. The Opdivo/Veyonda combination will be administered to two types of patients: (i) those with cancers known to be capable of responding to CIT (e.g. melanoma, lung and bladder cancers) showing progression after having stopped responding to CIT. (ii) those with cancer types (almost all other forms of cancer) shown by experience to be unlikely to respond to CIT (and therefore previously not exposed to CIT), and which are showing progression on chemotherapy or targeted therapy. This study is due to commence in a number of Australian cancer clinics in Q3 2021.